Our finding that CHURC1-FNTB is differentially expressed in B-ALL is novel, though work has been done to pursue this target as a cancer immunotherapy for a variety of different cancers, including AML [47,48]. Here, CHURC1 is linked to acute lymphoblastic leukemia.